Related Experiment Video
Updated: Dec 26, 2025
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
1.6K
[Targeted treatment in spondyloarthritis]
Laura Zanisi1, Michael John Nissen1
1Service de rhumatologie, Département de médecine, HUG, 1211 Genève 14.
Revue Medicale Suisse
|March 14, 2020
Summary
Choosing treatments for spondyloarthritis relies on patient characteristics due to a lack of clear prognostic markers. This approach aims to improve treatment response, but targeted therapies are still needed for all patient subgroups.
Area of Science:
- Rheumatology
- Immunology
- Clinical Medicine
Background:
- Spondyloarthritis treatment selection currently lacks defined prognostic markers and predictors of response.
- Therapy choice is based on stratifying clinical characteristics to enhance treatment efficacy.
Purpose of the Study:
- To review the current factors influencing disease-modifying antirheumatic drug (DMARD) selection in spondyloarthritis.
- To highlight the need for targeted treatment strategies in spondyloarthritis, addressing evidence gaps for specific patient subgroups.
Main Methods:
- Analysis of current clinical practice guidelines and treatment strategies for spondyloarthritis.
- Review of factors influencing DMARD choice, including disease phenotype, comorbidities, and patient preferences.
Main Results:
- DMARD selection is multifactorial, considering axial, peripheral, or entheseal disease patterns, psoriasis severity, extra-articular manifestations, and comorbidities.
- Patient preferences regarding administration route and frequency also guide treatment decisions.
Conclusions:
- Current spondyloarthritis treatment is personalized but not fully targeted due to a lack of evidence for certain patient groups.
- Further research is needed to develop targeted therapies and improve treatment outcomes for all individuals with spondyloarthritis.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
389
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
389
01:29Drugs for Treatment of Ulcerative Colitis in IBD
383
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
383
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
399
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
399
01:29Inflammatory Bowel Disease IV: Pharmacological Management
385
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
385
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
356
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
356